Clincosm LogoSign in Get a demo

Strategies to Continue Gynae-oncology Services in the Era of COVID-19 Outbreak: Concerns and Challenges in a Referral Centre in Malaysia

Sponsor
Universiti Kebangsaan Malaysia Medical Centre (Other)
Overall Status
Completed
CT.gov ID
NCT05043155
Collaborator
(none)
100
Enrollment
1
Location
8
Actual Duration (Months)
12.5
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A short survey involving 100 participants was conducted online to explore the understanding of Covid 19 pandemic impact and importance of vaccination among cancer survivors.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    100 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Cross-Sectional
    Official Title:
    Strategies to Continue Gynae-oncology Services in the Era of COVID-19 Outbreak: Concerns and Challenges in a Referral Centre in Malaysia
    Actual Study Start Date :
    Jan 1, 2021
    Actual Primary Completion Date :
    Sep 1, 2021
    Actual Study Completion Date :
    Sep 1, 2021

    Outcome Measures

    Primary Outcome Measures

    1. Vaccination refusal [8 months]

      Number of cancer survivors refuse vaccine

    2. Reason for Refusal of Vaccine [8 months]

      Number of cancer survivors refuse vaccine

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No

    Inclusion Criteria: Female cancer survivors or care-taker undergoing national covid 19 vaccine -

    Exclusion Criteria: Male, not cancer survivors

    -

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Dept O&G, UKM Medical Centre Kuala Lumpur Malaysia 56000

    Sponsors and Collaborators

    • Universiti Kebangsaan Malaysia Medical Centre

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Nirmala Chandralega Kampan, Associate Professor Dr, Universiti Kebangsaan Malaysia Medical Centre
    ClinicalTrials.gov Identifier:
    NCT05043155
    Other Study ID Numbers:
    • UKMMC202105
    First Posted:
    Sep 14, 2021
    Last Update Posted:
    Sep 14, 2021
    Last Verified:
    Sep 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nirmala Chandralega Kampan, Associate Professor Dr, Universiti Kebangsaan Malaysia Medical Centre
    Covid19
    Vaccination
    Gynaeoncology cancer
    Cancer survivor
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Sep 14, 2021